Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Earnings for Viking Therapeutics, Inc. (VKTX)
Earnings in 2023 (TTM): $-85,895,000
According to Viking Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-85,895,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Viking Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-85,895,000 | $-85,895,000 |
| 2022 | $-68,867,000 | $-67,379,000 |
| 2021 | $-54,990,000 | $-54,002,000 |
| 2020 | $-39,495,000 | $-36,051,000 |
| 2019 | $-25,779,000 | $-25,779,000 |
| 2018 | $-22,063,000 | $-22,063,000 |
| 2017 | $-20,577,665 | $-20,577,665 |
| 2016 | $-14,731,822 | $-14,731,822 |
| 2015 | $-23,403,988 | $-23,403,988 |
| 2014 | $-21,884,183 | $-21,884,183 |
| 2013 | $-146,247 | $-146,247 |
| 2012 | $-444 | $-444 |